上皮性卵巢癌中C-erbB_2、ER及PR的表达及其意义

Expression of C-erbB_2 Gene,ER and PR in Epithelial Ovarian Cancer

目的:探讨上皮性卵巢癌中C-erbB2基因产物、雌激素受体(ER)及孕激素受体(PR)的表达与肿瘤分期、分化及病理类型构成的关系。方法:收集经手术病理证实的上皮性卵巢癌病例115例,应用S-P免疫组化法检测其C-erbB2基因产物、ER及PR蛋白。结果:在115例上皮性卵巢癌中、ER及PR蛋白的表达率分别为52.17%、44.30%及39.13%。不同的卵巢癌临床期别中,晚期病例C-erbB2蛋白的阳性率高于早期病例(分别为33.73%、66.13%),差异有显著性(P=0.002);而ER、PR不同期别的阳性率无显著差异。3种蛋白在不同病理类型卵巢癌中的阳性率各不相同,但其构成比无明显差异。在肿瘤分化方面,低分化癌的ER、PR表达的阳性率低于高分化癌组,但其仅表现为一种趋势,无统计学意义;C-erbB2蛋白的表达在不同分化的肿瘤中差异不明显。结论:C-erbB2基因产物、ER及PR的表达在上皮性卵巢癌中都比较常见,C-erbB2蛋白过表达比例越高,疾病的临床期别越晚,则其生物学行为和预后就比较差。雌孕激素受体的检测有助于指导临床治疗。

Objective：To evaluate the relationship between the expression of C-erbB2 gene, ER, PR and pathological stage, pathologicaltype and histological grade in epithelial ovarian cancer. Mcthods：A total of 115 patients of epithelial ovarian cancer with operative and histologically-confirmed were assigend into the study. The C-erbB2 gene, ER and PR of 115 cases of ovarian carcinoma were labeled with S-P immunohistochemical method. Results： In EOC, the expression rate of C-erbB2 gene, ER and PR was 52. 17%, 44. 30% and 39. 13M, respectively. Overexpression of C-erbB2 protein was 33. 73% in early stage and 66.13% in advanced stage. The rate was more higher in the latter（P = 0. 002）. While expression rate of ER or PR in clinical stage, and positive rate of C-erbB2, ER, PR in histologically grade and pathological type showed no statistical difference.Conclusion：The expression of C-erbB2 gene, ER, PR were common in EOC. The higher overexpression rate of C-erbB2 protein was, the later clinical stage. It maybe reveal a bad biological characters and a poor prognosis. Detection of ER and PR would contribute to guide treatment.